

Quarter ending 31 December 2021 Investor Presentation

31 January 2022

Approved by the Board of Next Science

NEXT SCIENCE[®]

Disclosures

This presentation has been prepared by Next Science Limited (**Company**) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the *Corporations Act 2001* (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (**ASIC**). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at www.nextscience.com and www.asx.com.au. The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (**Forward Statements**). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the **Next Science Parties**) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in \$USD unless stated otherwise.

An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

Next Science has developed a world leading product portfolio to prevent or address the infections caused by biofilms in humans, based on our XBIO technology platform,

First sales: 2018

FDA 510(k) Clearances: 4

CE Mark Approvals 2

TGA Approvals 3

Patents 42

Patient usage > 250,000

US Hospitals using NXS technologies: 1835

Infection Prevention

- Surgical Site Infection
- Hospital acquired infections




Elimination of Biofilms and their incumbent bacteria

- Prosthetic Joint Infections
- Chronic Wounds
- Acne Treatments




160% Revenue growth (unaudited) 2021 V 2020



- **160% growth Year on Year**
- **29% growth 2H on 1H**
- **32% 4th Quarter on 3rd Quarter**

FY2021- New products, new clearances and new platforms for growth

- ✓ Q4 revenue US\$2.9M (unaudited) 32% growth on Q3
- ✓ FY21 revenue US\$8.9M (unaudited) 160% growth on prior year
- ✓ XPERIENCE™ continuing to gain traction in US market – 160 surgeons using product from 93 hospitals
- ✓ TELA Bio commenced sales of Site Guard Surgical Solution (white label of XPERIENCE™) to plastic and reconstructive surgery market in the US
- ✓ New distribution agreement with Zimmer Biomet for white label of XPERIENCE™ with sales expected to commence in H2 2022
- ✓ Reorganisation of commercial team
- ✓ Patent library extended to 42 Patents
- ✓ XPERIENCE™ approved in Australia
- ✓ Record year for Bactisure™ sales
- ✓ 4X expansion in BlastX™ direct customer base



New distribution agreement with Zimmer Biomet for white label version of XPERIENCE™

- New refreshed partnership with Zimmer Biomet – a world leader in hip and knee replacements. Next Science’s XPERIENCE™ intellectual property ownership and rights clarified. Zimmer expected to launch a white label of XPERIENCE™ into the US market in 2H 2022.
- Zimmer has over 2000 sales personnel and agents servicing the US joint replacement market and holds the number 1 market share position (based on revenue) in the US.
- The agreement has a 5 year term plus 5 year renewal option
- Next Science will continue to sell XPERIENCE™ directly into the US market and TELA Bio will continue to sell Site Guard Surgical Solution (white label version of XPERIENCE™)

Bactisure™ Surgical Lavage

Indication:
Treatment of
infected surgical
cavities &
implants

Market:
US 250,000
patients pa

Globally distributed
by Zimmer Biomet



BlastX™ Antimicrobial Wound Gel

Indication:
Treatment of
chronic wounds,
foot & leg ulcers,
bedsores, pressure
ulcers

Market:
US 8 million
patients pa

Market served
directly by Next
Science



Acne Treatments


Indication:
Treatment of
acne and
breakouts

Market:
Currently
offered in
Australia

Clinic sales through
AST
Online sales through
tbh skin care



Cash flow analysis



- Cash at bank
UD\$7.4M
- Debt free
- Q3 Net cash burn
US\$3.4M
- Q4 Net cash burn
US\$2.4M

- Direct surgical sales have started well in 2022 despite disruption in surgeries due to hospital staff shortages
- To accelerate product adoption, changes made in people, process and market access:
 - New management
 - Recruitment underway for President, North America
 - Sales reorganisation
 - CCO role removed with responsibilities assumed by Managing Director
 - Realigned sales force to split responsibilities for Commercial Hospitals and Federal Accounts
 - Refreshed distribution partnership with Zimmer Biomet adding XPERIENCE™ white label as a second product line and resolving dispute
 - Partnership with TELA Bio to provide dedicated representation to the plastic surgery market for surgical infection prevention products
 - Managing Director's assessment since arriving in the US in October 2021, reaffirms the significant and compelling opportunities for the products Next Science has brought to market

- New Zealand XPERIENCE™ launch with partner
- Australian XPERIENCE™ launch
- BlastX™ partnership Australia / New Zealand
- Key short term 2022 clinical studies - priorities
 - In vivo bioburden study
 - Inflammation study
 - Pull out study

NEXT SCIENCE[®]

ABN: 47 622 382 549

Suite 1902, 821 Pacific Highway Chatswood NSW
2067